Which one of the following factors is labelled as cytokine in the pathogenesis of systemic inflammatory response syndrome (SIRS) ?
**Core Concept**
Tumor Necrosis Factor (TNF) is a key pro-inflammatory cytokine involved in the pathogenesis of systemic inflammatory response syndrome (SIRS). SIRS is a clinical condition characterized by an exaggerated and uncontrolled inflammatory response to a variety of insults, including infections, trauma, burns, and severe medical conditions.
**Why the Correct Answer is Right**
Tumor Necrosis Factor is a crucial mediator of the inflammatory response, released by activated macrophages and other immune cells. It plays a central role in the activation of other immune cells, such as neutrophils and T-cells, and the induction of pro-inflammatory genes, leading to the production of other cytokines, chemokines, and adhesion molecules. This cascade of events contributes to the pathogenesis of SIRS, characterized by fever, tachycardia, tachypnea, and hypotension. TNF also promotes the production of other pro-inflammatory cytokines, such as IL-1 and IL-6, which further exacerbate the inflammatory response.
**Why Each Wrong Option is Incorrect**
**Option A:** Nitric oxide is a potent vasodilator and a key mediator of endothelial dysfunction, but it is not classified as a cytokine. Instead, it is produced by the enzyme nitric oxide synthase and plays a role in the regulation of vascular tone and blood pressure.
**Option B:** Complements are a group of proteins that play a crucial role in the innate immune response, but they are not cytokines. Complements are involved in the opsonization of pathogens, the activation of the complement cascade, and the recruitment of immune cells to the site of infection.
**Option C:** Leukotrienes are a group of eicosanoid mediators produced by the enzyme 5-lipoxygenase and are involved in the regulation of inflammatory responses. However, they are not cytokines and are not directly involved in the pathogenesis of SIRS.
**Clinical Pearl / High-Yield Fact**
TNF inhibitors, such as infliximab and etanercept, are used to treat autoimmune diseases, including rheumatoid arthritis and Crohn's disease, by blocking the action of TNF and reducing inflammation. Understanding the role of TNF in SIRS is essential for the management of patients with severe inflammatory conditions.
**✓ Correct Answer: D. Tumor Necrosis factor**